Physician profile
Scott E Wilkins
NPI 1912360348
$2,982.29
in general payments reported to CMS, 2019-2025
30 companies · $609 in 2025
The $609 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $120 · 2022: $492 · 2023: $744 · 2024: $1,018 · 2025: $609.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,304 · Education: $65.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,304.33 |
| Education | $65.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $477.78 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $408.90 | 2022-2025 | Vraylar |
| Astrazeneca Pharmaceuticals LP | $264.21 | 2019-2024 | Farxiga, Airsupra, Breztri |
| Xeris Pharmaceuticals, INC. | $201.41 | 2022-2025 | Gvoke Hypopen, Keveyis |
| Astellas Pharma US INC | $182.62 | 2023-2025 | Veozah, Myrbetriq |
| Novo Nordisk INC | $182.21 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $167.86 | 2022-2025 | |
| Amgen INC. | $157.18 | 2022-2025 | Evenity, Prolia |
| Exact Sciences Corporation | $123.15 | 2023-2024 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $107.27 | 2022-2023 | Ofev, Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $81.79 | 2022-2024 | Xifaxan |
| Sanofi-Aventis U.S. LLC | $72.37 | 2019-2022 | |
| Dynavax Technologies Corporation | $59.40 | 2022-2024 | Heplisav-B |
| Sanofi Pasteur INC. | $50.24 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $49.79 | 2023-2024 | Gardasil 9, Gardasil, Vaxneuvance |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $46.52 | 2022 | |
| Inspire Medical Systems, INC. | $45.32 | 2024-2025 | Inspire |
| Pfizer INC. | $41.29 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $41.04 | 2023 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $32.07 | 2025 | Eliquis |
| Dexcom, INC. | $29.63 | 2022 | |
| Glaxosmithkline, LLC. | $29.23 | 2019-2025 | Shingrix, Arexvy |
| Phathom Pharmaceuticals, INC. | $18.76 | 2024 | Voquezna |
| Shield Therapeutics INC | $18.10 | 2023 | Accrufer |
| Optinose US, INC. | $17.93 | 2024 | |
| Idorsia Pharmaceuticals US INC | $17.14 | 2022 | |
| Vbi Vaccine (Delaware) INC. | $16.69 | 2022 | |
| Seqirus USA INC | $15.88 | 2023 | Flucelvax Quadrivalent, Fluad Quadrivalent |
| Biohaven Pharmaceutical Holding Company LTD. | $14.54 | 2022 | |
| Amarin Pharma, INC. | $11.97 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Wilkins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.